As of September 30, 2026, Enliven Therapeutics, Inc. carries a market capitalization of 3.37B, placing it among publicly traded companies globally. Its enterprise value stands at 2.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.37B |
| Enterprise Value | 2.49B |
Enliven Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 18, 2027.
| Earnings Date | 3/18/2027 |
As of September 30, 2026, Enliven Therapeutics, Inc. has 73.56M shares outstanding.
| Shares Outstanding | 73.56M |
These figures are as of September 30, 2026.
| PB Ratio | 3.85 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | -46.45 |
| P/OCF Ratio | -46.59 |
As of September 30, 2026, Enliven Therapeutics, Inc. maintains a current ratio of 45.95, meaning it holds 46.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 45.95 |
| Quick Ratio | 45.41 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | -0.01 |
Over the twelve months ended September 30, 2026, Enliven Therapeutics, Inc. posted a negative return on equity (ROE) of -16.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 60.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -16.77 |
| Return on Assets (ROA) | -16.35 |
| Employee Count | 60.00 |
As of the close on November 16, 2026, Enliven Therapeutics, Inc.'s stock has gained approximately 115.77% over the past 52 weeks. The 50-day moving average sits at 46.20, while the 200-day moving average is 43.94.
| 52-Week Price Change | 115.77% |
| 50-Day Moving Average | 46.20 |
| 200-Day Moving Average | 43.94 |
Over the twelve months ended September 30, 2026, Enliven Therapeutics, Inc. generated - - in revenue and converted that into -113.48M in net income, yielding earnings per share of -1.69. EBITDA reached -135.28M, while operating income came in at -135.36M.
| Operating Income | -135.36M |
| Pretax Income | -113.48M |
| Net Income | -113.48M |
| EBITDA | -135.28M |
| EBIT | -135.36M |
| Earnings Per Share (EPS) | -1.69 |
As of September 30, 2026, Enliven Therapeutics, Inc. holds 884.35M in cash and equivalents against 1.32M in total debt, resulting in a net debt position of -151.67M. Total book value stands at 876.95M, with working capital of 875.28M providing operational flexibility.
| Cash & Cash Equivalents | 884.35M |
| Total Debt | 1.32M |
| Net Debt | -151.67M |
| Equity (Book Value) | 876.95M |
| Book Value Per Share | 11.92 |
| Working Capital | 875.28M |
Enliven Therapeutics, Inc. produced -66.21M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -193,000.00 in capital expenditures, free cash flow totaled -66.41M - equivalent to -0.99 per share.
| Operating Cash Flow | -66.21M |
| Capital Expenditures | -193,000.00 |
| Free Cash Flow | -66.41M |
| FCF Per Share | -0.99 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -2.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.13, meaning Enliven Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -14.13 |
| FCF Yield | -2.15 |
Enliven Therapeutics, Inc.'s most recent stock split took place on February 24, 2023 with a 4:1 split ratio.
| Last Split Date | 2/24/2023 |
| Split Ratio | 4:1 |
As of September 30, 2026, Enliven Therapeutics, Inc. has an Altman Z-Score of 99.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 99.77 |